Shire has revealed that the European Commission has approved Adynovi (antihaemophilic factor (recombinant), PEGylated) for on-demand and prophylactic use in adult patients with haemophilia A.
Adynovi, approved as Adynovate in the US, Japan, Canada and Colombia, is an extended half-life recombinant factor VIII (rFVIII) treatment built on Advate, and is designed to extend the time between treatments by lasting longer in the blood compared to unmodified antihaemophilic factor. It is to be taken twice weekly.
